Literature DB >> 8047821

Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients.

E Solcia1, L Villani, R Fiocca, O Luinetti, R Boldorini, E Trespi, M Perego, C Alvisi, M Lazzaroni, G Bianchi Porro.   

Abstract

The incidence and mean score of Helicobacter pylori-related, active antroduodenitis, lesions of superficial antral epithelium and duodenal gastric-type metaplasia were higher in endoscopic biopsies from a large series of patients with duodenal ulcer, when compared with asymptomatic patients or patients with non-ulcer dyspepsia. In 65 out of 73 patients with duodenal ulcer who could be followed up, H. pylori was eradicated using a combination of amoxycillin, 3 g daily, metronidazole, 1 g daily, and omeprazole, 20 mg daily. Rapid and permanent (6-month follow-up) abolition of both gastroduodenitis activity and lesions of the gastric surface epithelium was observed in these 65 patients. There was also a progressive decrease in total immune-inflammatory cells but without a substantial change in duodenal gastric-type metaplasia. Similar, but transient and quantitatively less prominent, improvements were observed in the antroduodenal mucosa, which had been temporarily cleared of H. pylori by treatment with omeprazole alone. Conversely, increased gastritis activity, epithelial lesions and immune-inflammatory cell scores were found in the short term in the corpus mucosa, which was not cleared of H. pylori after omeprazole treatment. It is concluded that, of the various H. pylori-related mucosal changes, antroduodenitis activity and antral epithelial lesions most closely reflect the severity of mucosal damage and are probably the most important factors in duodenal ulcerogenesis. Their complete and rapid suppression after bacterial eradication may be a key factor in preventing ulcer relapse.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8047821

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  9 in total

1.  Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection.

Authors:  Ala I Sharara; Fayez S Sarkis; Mustapha M El-Halabi; Ahmad Malli; Nabil M Mansour; Cecilio Azar; Mohamad A Eloubeidi; Fadi H Mourad; Kassem Barada; Ismail Sukkarieh
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

2.  Effect of interleukin-8 on histamine release from totally isolated vascularly perfused rat stomach.

Authors:  Koji Yakabi; Shoki Ro; Seiichi Miura; Teruyuki Tanaka; Shino Ohno; Junichi Kawashima; Susumu Kurosawa; Takashi Nakamura
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

3.  HpSS: a new silver staining method for Helicobacter pylori.

Authors:  C Doglioni; M Turrin; E Macrì; C Chiarelli; B Germanà; M Barbareschi
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

4.  Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.

Authors:  G Bianchi Porro; F Parente; V Imbesi; F Montrone; I Caruso
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 5.  Elevated risk for gastric adenocarcinoma can be predicted from histomorphology.

Authors:  Michael Vieth; Mandred Stolte
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

6.  Interleukin-8 enhances tetragastrin-stimulated acid secretion in vivo.

Authors:  K Yakabi; H Mimura; H Iwabuchi; S Ro; T Nakamura
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

7.  Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of helicobacter pylori in duodenal ulcer patients. A controlled study.

Authors:  F Parente; G Maconi; O Sangaletti; M Minguzzi; L Vago; G Bianchi Porro
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

8.  Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer.

Authors:  K E McColl; A el-Nujumi; L S Murray; E M el-Omar; A Dickson; A W Kelman; T E Hilditch
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

Review 9.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.